UY35036A - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents
Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10aInfo
- Publication number
- UY35036A UY35036A UY0001035036A UY35036A UY35036A UY 35036 A UY35036 A UY 35036A UY 0001035036 A UY0001035036 A UY 0001035036A UY 35036 A UY35036 A UY 35036A UY 35036 A UY35036 A UY 35036A
- Authority
- UY
- Uruguay
- Prior art keywords
- phosphodiesterase
- type
- inhibiting compounds
- new
- new inhibiting
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702005P | 2012-09-17 | 2012-09-17 | |
| US201261702371P | 2012-09-18 | 2012-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35036A true UY35036A (es) | 2014-03-31 |
Family
ID=49226152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035036A UY35036A (es) | 2012-09-17 | 2013-09-17 | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9388180B2 (https=) |
| EP (1) | EP2895489B1 (https=) |
| JP (1) | JP2015528484A (https=) |
| KR (1) | KR20150056844A (https=) |
| CN (1) | CN105102461A (https=) |
| AR (1) | AR092595A1 (https=) |
| AU (1) | AU2013314244A1 (https=) |
| BR (1) | BR112015005935A2 (https=) |
| CA (1) | CA2883910A1 (https=) |
| HK (1) | HK1206728A1 (https=) |
| IL (1) | IL237626A0 (https=) |
| IN (1) | IN2015DN01900A (https=) |
| MX (1) | MX2015003419A (https=) |
| RU (1) | RU2015114331A (https=) |
| SG (1) | SG11201502074YA (https=) |
| TW (1) | TW201418264A (https=) |
| UY (1) | UY35036A (https=) |
| WO (1) | WO2014041175A1 (https=) |
| ZA (1) | ZA201501458B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015117950A (ru) | 2012-10-26 | 2016-12-20 | Ф. Хоффманн-Ля Рош Аг | 3,4-дизамещенный 1н-пиразол и 4,5-дизамещенный тиазол в качестве ингибиторов тирозинкиназы syk |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN111592495A (zh) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US7057042B2 (en) * | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| WO2005120514A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| AU2005282721A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| WO2006035061A1 (en) * | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting bi-cyclic pyrimidines |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| US20100222353A1 (en) | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| WO2007098169A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| MX2008010671A (es) | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
| WO2007096743A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| WO2007100880A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| US20070299067A1 (en) | 2006-03-08 | 2007-12-27 | Ruiping Liu | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| PT2057153E (pt) | 2006-07-10 | 2012-11-14 | Lundbeck & Co As H | Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143392A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| KR20100110804A (ko) * | 2007-11-30 | 2010-10-13 | 와이어쓰 엘엘씨 | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진 |
| EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| JP5748659B2 (ja) | 2008-06-10 | 2015-07-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| WO2010054260A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
| US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
-
2013
- 2013-09-16 EP EP13765695.5A patent/EP2895489B1/en not_active Not-in-force
- 2013-09-16 HK HK15107215.7A patent/HK1206728A1/xx unknown
- 2013-09-16 KR KR1020157009897A patent/KR20150056844A/ko not_active Withdrawn
- 2013-09-16 RU RU2015114331A patent/RU2015114331A/ru not_active Application Discontinuation
- 2013-09-16 CA CA2883910A patent/CA2883910A1/en not_active Abandoned
- 2013-09-16 JP JP2015531593A patent/JP2015528484A/ja not_active Withdrawn
- 2013-09-16 SG SG11201502074YA patent/SG11201502074YA/en unknown
- 2013-09-16 AU AU2013314244A patent/AU2013314244A1/en not_active Abandoned
- 2013-09-16 MX MX2015003419A patent/MX2015003419A/es unknown
- 2013-09-16 CN CN201380048224.3A patent/CN105102461A/zh active Pending
- 2013-09-16 BR BR112015005935A patent/BR112015005935A2/pt not_active IP Right Cessation
- 2013-09-16 IN IN1900DEN2015 patent/IN2015DN01900A/en unknown
- 2013-09-16 WO PCT/EP2013/069173 patent/WO2014041175A1/en not_active Ceased
- 2013-09-17 TW TW102133710A patent/TW201418264A/zh unknown
- 2013-09-17 US US14/029,142 patent/US9388180B2/en not_active Expired - Fee Related
- 2013-09-17 UY UY0001035036A patent/UY35036A/es not_active Application Discontinuation
- 2013-09-17 AR ARP130103326A patent/AR092595A1/es unknown
-
2015
- 2015-03-03 ZA ZA2015/01458A patent/ZA201501458B/en unknown
- 2015-03-09 IL IL237626A patent/IL237626A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR092595A1 (es) | 2015-04-29 |
| EP2895489B1 (en) | 2017-10-18 |
| KR20150056844A (ko) | 2015-05-27 |
| US20140107126A1 (en) | 2014-04-17 |
| CN105102461A (zh) | 2015-11-25 |
| HK1206728A1 (en) | 2016-01-15 |
| IN2015DN01900A (https=) | 2015-08-07 |
| WO2014041175A1 (en) | 2014-03-20 |
| SG11201502074YA (en) | 2015-05-28 |
| ZA201501458B (en) | 2018-11-28 |
| AU2013314244A1 (en) | 2015-03-12 |
| MX2015003419A (es) | 2015-09-23 |
| US9388180B2 (en) | 2016-07-12 |
| AU2013314244A8 (en) | 2015-04-30 |
| CA2883910A1 (en) | 2014-03-20 |
| IL237626A0 (en) | 2015-04-30 |
| EP2895489A1 (en) | 2015-07-22 |
| TW201418264A (zh) | 2014-05-16 |
| RU2015114331A (ru) | 2016-11-10 |
| JP2015528484A (ja) | 2015-09-28 |
| BR112015005935A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000251A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| CR20120277A (es) | Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa | |
| BR112015020795A2 (pt) | derivados de pirazol novos | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| UA116395C2 (uk) | ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| BR112015009600A2 (pt) | piridina-2-amidas úteis como agonistas cb2 | |
| CO6741154A2 (es) | Compuestos de triazolopiridina | |
| CR20160459A (es) | Nuevos derivados de piridina | |
| UA107671C2 (en) | N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives | |
| BR112018011562A2 (pt) | novos derivados de fenil | |
| UA106889C2 (uk) | Похідні n1-ацил-5-фторпіримідинону | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| UY35036A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| AR091888A1 (es) | Compuestos de urea y su uso como inhibidores de enzimas | |
| BR112014019220A8 (pt) | Novos derivados de pirrolidina | |
| BR112015030824A2 (pt) | novos derivados de tetrazolona | |
| CO7200259A2 (es) | Nuevos derivados de piridina | |
| CO2018007756A2 (es) | Nuevos derivados pirrolidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20210617 |